PROPANC BIOPHARMA, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-58.9M | $-1.8M | $-2.7M | $-2.7M | $-2.0M | $-4.7M | $-5.8M | $-7.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $297 | $1.7K | $2.0K | $2.0K | $2.5K | $2.3K | $2.2K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.6M | — | $2.4K | $72.5K | $82.9K | $300.4K | — | $516.1K |
| Net Cash from Operating Activities | $-405.2K | $-935.1K | $-1.1M | $-1.4M | $-1.1M | $-1.8M | $-2.1M | $-2.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $2.9K | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | $-2.9K | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $490.8K | $941.9K | $1.1M | $1.5M | $1.1M | $1.9M | $2.1M | $2.4M |
| Net Change in Cash | $-9.0K | $11.0K | $6.0K | $1.8K | $-64.8K | $64.6K | $-17.5K | $-49.1K |
| Free Cash Flow | — | — | — | — | — | — | $-2.1M | — |